Repeated low-level red-light therapy Archives - Insight https://www.insightnews.com.au/ophthalmic-treatments/light-based-therapy/repeated-low-level-red-light-therapy/ Presented by Prime Creative Media Tue, 06 Feb 2024 00:32:39 +0000 en-US hourly 1 https://www.insightnews.com.au/wp-content/uploads/2024/02/cropped-Insight-favicon-32x32.png Repeated low-level red-light therapy Archives - Insight https://www.insightnews.com.au/ophthalmic-treatments/light-based-therapy/repeated-low-level-red-light-therapy/ 32 32 Eyerising International refutes ‘inaccurate claims’ in University of Houston red light myopia study https://www.insightnews.com.au/eyerising-international-refutes-inaccurate-claims-in-university-of-houston-red-light-myopia-study/ Tue, 06 Feb 2024 00:32:39 +0000 https://www.insightnews.com.au/?p=39502 Eyerising red light study
The Eyerising Myopia Management Device is approved in over 30 countries, including Australia. Image: Eyerising International.

  Australian medical device company Eyerising International says its device has been “misrepresented” in a recent study over the safety of repeated low-level red-light (RLRL) in myopia management.Read More

The post Eyerising International refutes ‘inaccurate claims’ in University of Houston red light myopia study appeared first on Insight.

]]> Eyerising red light study
The Eyerising Myopia Management Device is approved in over 30 countries, including Australia. Image: Eyerising International.
  Australian medical device company Eyerising International says its device has been “misrepresented” in a recent study over the safety of repeated low-level red-light (RLRL) in myopia management.
Read More

The post Eyerising International refutes ‘inaccurate claims’ in University of Houston red light myopia study appeared first on Insight.

]]> Rare complication case: Eyerising International addresses safety questions https://www.insightnews.com.au/rare-complication-case-eyerising-international-addresses-safety-questions/ Tue, 10 Oct 2023 20:44:04 +0000 https://www.insightnews.com.au/?p=37831
Over a 12-month period, the therapy has shown 69.4% efficacy in controlling axial length elongation.

The post Rare complication case: Eyerising International addresses safety questions appeared first on Insight.

]]>
Over a 12-month period, the therapy has shown 69.4% efficacy in controlling axial length elongation.
Eyerising International has addressed questions over the safety of its repeated-low level red-Light (RLRL) treatment for myopia management, following two case reports on a probable “super responder”
Read More

The post Rare complication case: Eyerising International addresses safety questions appeared first on Insight.

]]>